University of Glasgow graduate and Young Alumnus of the Year 2010, Professor Patrick Gunning (BSc 2001, PhD 2005), has officially launched the third company to come out of the Gunning Group’s research, Dunad Therapeutics. 

Dunad Therapeutics is a transformational, mono-valent small molecule protein degradation company aiming to rapidly expand the pipeline of orally bioavailable and cns-accessible degraders.

Dunad has secured £5 million initial financing from Epidarex Capital, a transatlantic venture firm, based in Edinburgh, that specialises in seeding and building exceptional early-stage life science companies.

The University is always pleased to recognise and celebrate the accomplishments of our alumni, and we wish Professor Gunning all the best with Dunad Therapeutics.

First published: 7 April 2021

<< Noticeboard


Portrait of Professor Patrick Gunning